A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

← catalyst calendar

NCT07465757 · readout in 590 d

Sponsored by Puma Biotechnology, Inc. (industry) · PBYI — their whole pipeline →.

Phase

Phase 2

Status

Not yet recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

50estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-09-30

estimated

When the study began enrolling

Primary completion

2028-03-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-09-30

estimated

The whole study's end, after follow-up

First posted

2026-03-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-12

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Small Cell Lung Cancer ( SCLC )

Interventions

Drug: Alisertib — also filed as PB-8237, MLN8237
Drug: Alisertib — also filed as PB-8237, MLN8237
Drug: Alisertib — also filed as PB-8237, MLN8237
Drug: Alisertib — also filed as PB-8237, MLN8237
Drug: Alisertib — also filed as PB-8237, MLN8237
Drug: Paclitaxel

Primary outcome

what the primary-completion date above is the date OF

Percentage of Participants with Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events)

measured From date of first dose through last dose plus 28 days, assessed up to 24 months

Permalink · PBYI's whole pipeline · Catalyst calendar · Every registered study · What changed